Back to top

Analyst Blog

Becton, Dickinson and Company (BDX - Analyst Report) has globally launched its latest glass prefillable syringe system, the BD Neopak. The advanced device is used for biopharmaceutical injectable drug delivery.

The BD Neopak Glass Prefillable Syringe provides high quality container and device integration support, which in turn allows its pharmaceutical customers to safely deliver drugs to patients. The fully indexed lines on the syringe with no possibility of glass-to-glass contact limit visual defects and strengthens the quality of the glass. The new process also reduces silicone quantity.

The unique design of the prefillable syringe system helps to optimize filling of biologic drugs, among the top selling drugs in the world. The BD XSi cross-linked silicone technology and the ultralow tungsten technology in the BD Neopak, further aids BD’s pharmaceutical clients to market sensitive drugs.

BDX will provide additional services such as customized drug compatibility assessments, functional requirements (drug and system related) as well as registration and post-launch help to aid drug development with the BD Neopak.

The worldwide commercial launch of this new offering should boost the company’s Pharmaceutical System division’s revenues under the BD Medical segment. In the last reported quarter, sales of this franchise were up 3.0% (up 2.4% in constant currency) to $291.4 million.

The stock currently carries a Zacks Rank #2 (Buy). We remain encouraged by the company’s solid fiscal second-quarter results, which exceeded expectations. Moreover, the upward revision in guidance for the ongoing fiscal reflects positive drivers.

Becton Dickinson’s preeminent global healthcare products franchise is partly insulated from volatile macroeconomic conditions and structural deficiencies elsewhere in the healthcare delivery field.

Other medical stocks that warrant a look include CONMED (CNMD - Analyst Report), The Cooper Companies (COO - Analyst Report) and West Pharmaceutical Services (WST - Snapshot Report). All the stocks carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%